Form 4: Hims & Hers CLO Granted 188,111 Restricted Stock Units

Hims & Hers Health, Inc.'s Chief Legal Officer, Soleil Boughton, was granted 188,111 Restricted Stock Units subject to a four-year service-based vesting schedule.

Summary

• Soleil Boughton, Chief Legal Officer of Hims & Hers Health, Inc., was granted 188,111 Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of Class A Common Stock.
• The RSUs are subject to a service-based vesting requirement over a 4-year period.
• Vesting will occur in substantially equal quarterly installments on March 15, June 15, September 15, and December 15.
• The first vesting date for these RSUs is scheduled for June 15, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a standard executive compensation event, aligning the Chief Legal Officer's interests with long-term shareholder value through a service-based RSU grant.

Positives

• The grant of Restricted Stock Units aligns the Chief Legal Officer's long-term interests with those of the shareholders, incentivizing sustained performance and retention.
• Service-based vesting over four years promotes executive stability and commitment to the company's strategic goals.

Negatives

• The RSUs are not immediately exercisable or convertible, requiring the Chief Legal Officer to remain employed for the vesting schedule to be satisfied.
• The value of the RSUs upon vesting is dependent on the future market price of Hims & Hers Class A Common Stock, introducing market risk.

Risks

• The RSUs are subject to a service-based vesting requirement, meaning the recipient must remain employed by the company for the specified period to receive the shares.
• The ultimate value realized from the RSUs is dependent on the future market price of Hims & Hers Class A Common Stock, which can fluctuate.

Future Outlook

The future outlook for Soleil Boughton includes the potential to acquire 188,111 shares of Class A Common Stock over a four-year period, contingent on continued service to Hims & Hers Health, Inc. The vesting schedule indicates a commitment to long-term executive retention.

Industry Context

StockSavvy.ai notes that the grant of Restricted Stock Units to a Chief Legal Officer is a standard practice in the healthcare technology sector and broader corporate landscape. This form of equity compensation is widely used to attract, retain, and motivate key executives by aligning their financial incentives with the long-term performance of the company and shareholder value creation.

Comparison to Industry Standards

• RSU grants with multi-year service-based vesting are a common form of executive compensation across various industries, including healthcare technology, similar to practices observed at companies like Teladoc Health or GoodRx.
• The structure aims to incentivize long-term retention and performance, a standard approach for executive equity awards in publicly traded companies.

Related Party Transactions

• The grant of 188,111 Restricted Stock Units to Soleil Boughton, the Chief Legal Officer, constitutes a related party transaction as it involves compensation to an executive officer of the company.

Stakeholder Impact

• Shareholders: The RSU grant represents potential future dilution as shares will be issued upon vesting, but it also serves to align executive incentives with shareholder interests.
• Employees: This transaction is specific to an executive and does not directly impact the broader employee base, though it reflects the company's executive compensation strategy.

Next Steps

• The RSUs will begin vesting on June 15, 2026, and continue quarterly over a four-year period, contingent on Soleil Boughton's continued service.

Key Dates

Keywords

Hims & Hers Health, HIMS, Restricted Stock Units, RSU grant, executive compensation, insider transaction, Form 4, equity award, vesting schedule